^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Colon Cancer
    Drug:gedatolisib (PF-05212384) (mTOR inhibitor, PI3K inhibitor, mTORC1 inhibitor, mTORC2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

    Excerpt:
    In vivo regimens to test PKI-587 efficacy in the HCT116 [K-Ras, PIK3CA (H1047R)] model were guided by in vitro data. In vitro, PKI-587 inhibited HCT116 growth (IC50 = 8 nmol/L) and suppressed p-Akt (T308) at 30 nmol/L or more after 18 hours of exposure ...Combined, irinotecan (40 mg/kg) and PKI-587 (12.5 mg/kg), day 1, 5, 9 regimen, prevented HCT116 tumor size increase in a 13-day study ...
    Secondary therapy:
    irinotecan
    DOI:
    10.1158/1078-0432.CCR-10-1694